Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Loree, Jonathan M.
Topham, James T.
Kennecke, Hagen Fritz
Feilotter, Harriet
Lee, Young S.
Virk, Shakeel
Kopetz, Scott
Duose, Dzifa Yawa
Manyam, Ganiraju C.
Morris, Jeffrey S.
Maru, Dipen M.
Renouf, Daniel
Jonker, Derek J.
Tu, Dongsheng
O'Callaghan, Christopher J.
Chen, Eric Xueyu
机构：
[1] Genome Sci Ctr, Vancouver, BC, Canada
[2] Providence Canc Inst, Portland, OR USA
[3] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada
[4] AstraZeneca, Translat Med, Gaithersburg, MD USA
[5] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA
[8] Univ Penn, Philadelphia, PA USA
[9] MD Anderson Canc Ctr, Houston, TX USA
[10] Univ British Columbia, Vancouver, BC, Canada
[11] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[12] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3551
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab plus tremelimumab (D plus T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
    Loree, Jonathan M.
    Topham, James T.
    Kennecke, Hagen F.
    Feilotter, Harriet
    Keshavarz-Rahaghi, Faeze
    Lee, Young S.
    Li Weimin
    Quinn, Katie
    Banks, Kimberly
    Renouf, Daniel John
    Jonker, Derek J.
    Tu Dongsheng
    O'Callaghan, Christopher J.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
    Chen, Eric Xueyu
    Jonker, Derek J.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [3] Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
    Loree, Jonathan M.
    Titmuss, Emma
    Topham, James T.
    Kennecke, Hagen F.
    Feilotter, Harriet
    Virk, Shakeel
    Lee, Young S.
    Banks, Kimberly
    Quinn, Katie
    Karsan, Aly
    Renouf, Daniel J.
    Jonker, Derek J.
    Tu, Dongsheng
    O'Callaghan, Chris J.
    Chen, Eric X.
    CLINICAL CANCER RESEARCH, 2024, 30 (15) : 3189 - 3199
  • [4] CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
    Chen, Eric Xueyu
    Jonker, Derek J.
    Loree, Jonathan M.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
    Lenz, Heinz -Josef
    Ou, Fang-Shu
    Venook, Alan P.
    Hochster, Howard S.
    Niedzwiecki, Donna
    Goldberg, Richard M.
    Mayer, Robert J.
    Bertagnolli, Monica M.
    Blanke, Charles David
    Zemla, Tyler
    Qu, Xueping
    Innocenti, Federico
    Kabbarah, Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] THE COST EFFECTIVENESS OF CETUXIMAB PLUS BEST SUPPORTIVE CARE (BSC) VERSUS BSC ALONE IN LAST LINE FOR KRAS WILD TYPE METASTATIC COLORECTAL CANCER PATIENT POPULATION
    Chaugule, S.
    Hay, J.
    VALUE IN HEALTH, 2012, 15 (04) : A219 - A219
  • [7] A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)
    Kuboki, Y.
    Yoshino, T.
    Yamazaki, K.
    Nishina, T.
    Komatsu, Y.
    Baba, H.
    Tsuji, A.
    Yamaguchi, K.
    Muro, K.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S392 - S392
  • [8] Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC).
    Kim, Tae Won
    Elme, Anneli
    Park, Joon Ho
    Udrea, Anghel Adrian
    Manojlovic, Nebojsa S.
    Guan, Xuesong
    Jung, A. Scott
    Vrdoljak, Eduard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.
    Kim, Tae Won
    Elme, Anneli
    Kusic, Zvonko
    Park, Joon Oh
    Udrea, Anghel Adrian
    Kim, Sun Young
    Ahn, Joong Bae
    Valencia, Ricardo Villalobos
    Srinivasan, Krishnan
    Bilic, Ante
    Manojlovic, Nebojsa
    Dong, Jun
    Guan, Xuesong
    Lofton-Day, Catherine
    Jung, A. Scott
    Vrdoljak, Eduard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] RESULTS OF A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL (CORRECT) OF REGORAFENIB PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WHO HAVE PROGRESSED AFTER STANDARD THERAPIES
    Yoshino, T.
    Van Cutsem, E.
    Sobrero, A. F.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. -J.
    Cihon, F.
    Wagner, A.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 7 - 7
12345